Univercells completed the acquisition of SynHelix from AdBio partners.

Univercells, a biotechnology company, completed the acquisition of SynHelix, a biotechnology company developing scalable and automated DNA synthesis, from AdBio partners, a life sciences venture capital firm. Financial terms were not disclosed. “The development of SynHelix’s synthetic DNA production platform is highly complementary to Quantoom’s flagship RNA platform, as linear DNA is one of the critical inputs of RNA production. This deal will unlock expertise, knowledge and IP on de novo DNA synthesis, where the SynHelix team holds valuable experience. Both companies’ founders, employees and investors share the same vision and mission, aiming at making new and complex biopharmaceuticals available to all and strongly believe in technology-driven affordability. In addition, the acquisition enables us to tap into the dynamic French biotech ecosystem,” José Castillo, Quantoom Biosciences CEO.